Literature DB >> 31526813

Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings.

Anne Zwartsen1, Tessa de Korte2, Peter Nacken3, Dylan W de Lange4, Remco H S Westerink5, Laura Hondebrink6.   

Abstract

The use of recreational drugs, including new psychoactive substances (NPS), is paralleled by emergency department visits of drug users with severe cardiotoxicity. Drug-induced cardiotoxicity can be the (secondary) result of increased norepinephrine blood concentrations, but data on potential drug-induced direct effects on cardiomyocyte function are scarce. The presence of hundreds of NPS therefore calls for efficient screening models to assess direct cardiotoxicity. We investigated effects of four reference compounds (3-30 nM dofetilide, nifedipine and isoproterenol, and 1-10 μM mexiletine) and six recreational drugs (0.01-100 μM cocaine, 0.01-1000 μM amphetamine, MDMA, 4-fluoroamphetamine, α-PVP and MDPV) on cardiomyocyte function (beat rate, spike amplitude and field potential duration (FPD ≈ QT interval in ECGs)), using Pluricyte® human-induced pluripotent stem cell (hiPSC)-derived cardiomyocytes cultured on ready-to-use CardioPlate™ multi-well microelectrode arrays (mwMEAs). Moreover, the effects of exposure to recreational drugs on cell viability were assessed. Effects of reference compounds were in accordance with the literature, indicating the presence of hERG potassium (dofetilide), sodium (mexiletine) and calcium (nifedipine) channels and α-adrenergic receptors (isoproterenol). All recreational drugs decreased the spike amplitude at 10-100 μM. All amphetamine-type stimulants and α-PVP decreased the beat rate at 300 μM, while cocaine and MDPV did so at 10 μM and 30 μM, respectively. All drugs increased the FPD, however at varying concentrations. MDMA, MDPV and amphetamine affected cardiomyocyte function at concentrations relevant for human exposure, while other drugs affected cardiomyocyte function only at higher concentrations (≥ 10 μM). Cell viability was only mildly affected at concentrations well above the lowest concentrations affecting cardiomyocyte function. We demonstrate that MEA recordings of hiPSC-derived cardiomyocytes enable screening for acute, direct effects on cardiomyocyte function. Our data further indicate that tachycardia in patients exposed to recreational drugs is likely due to indirect drug effects, while prolonged repolarization periods (prolonged QTc interval) could (partly) result from direct drug effects on cardiomyocyte function.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Designer drugs; Drug-induced cardiotoxicity; Functional cardiotoxicity screening; Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs); Microelectrode array (MEA); New psychoactive substances (NPS); QT prolongation

Year:  2019        PMID: 31526813     DOI: 10.1016/j.yjmcc.2019.09.007

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  15 in total

Review 1.  Stimulant Drugs of Abuse and Cardiac Arrhythmias.

Authors:  Paari Dominic; Javaria Ahmad; Hajra Awwab; Md Shenuarin Bhuiyan; Christopher G Kevil; Nicholas E Goeders; Kevin S Murnane; James C Patterson; Kristin E Sandau; Rakesh Gopinathannair; Brian Olshansky
Journal:  Circ Arrhythm Electrophysiol       Date:  2021-12-28

2.  In vitro-in silico-based prediction of inter-individual and inter-ethnic variations in the dose-dependent cardiotoxicity of R- and S-methadone in humans.

Authors:  Miaoying Shi; Yumeng Dong; Hans Bouwmeester; Ivonne M C M Rietjens; Marije Strikwold
Journal:  Arch Toxicol       Date:  2022-05-23       Impact factor: 6.168

3.  Myosin light chain 2 marks differentiating ventricular cardiomyocytes derived from human embryonic stem cells.

Authors:  Xiao-Ling Luo; Peng Zhang; Xiangyuan Liu; Shiqian Huang; Sen-Le Rao; Qiurong Ding; Huang-Tian Yang
Journal:  Pflugers Arch       Date:  2021-05-24       Impact factor: 3.657

4.  Integrating in vitro data and physiologically based kinetic modeling-facilitated reverse dosimetry to predict human cardiotoxicity of methadone.

Authors:  Miaoying Shi; Hans Bouwmeester; Ivonne M C M Rietjens; Marije Strikwold
Journal:  Arch Toxicol       Date:  2020-05-04       Impact factor: 5.153

Review 5.  Beauvericin and Enniatins: In Vitro Intestinal Effects.

Authors:  Alessia Bertero; Paola Fossati; Doriana Eurosia Angela Tedesco; Francesca Caloni
Journal:  Toxins (Basel)       Date:  2020-10-29       Impact factor: 4.546

6.  Impact of High-Dose Irradiation on Human iPSC-Derived Cardiomyocytes Using Multi-Electrode Arrays: Implications for the Antiarrhythmic Effects of Cardiac Radioablation.

Authors:  Jae Sik Kim; Seong Woo Choi; Yun-Gwi Park; Sung Joon Kim; Chang Heon Choi; Myung-Jin Cha; Ji Hyun Chang
Journal:  Int J Mol Sci       Date:  2021-12-29       Impact factor: 5.923

7.  Electrically stimulable indium tin oxide plate for long-term in vitro cardiomyocyte culture.

Authors:  Sung-Hwan Moon; Young-Woo Cho; Hye-Eun Shim; Jae-Hak Choi; Chan-Hee Jung; In-Tae Hwang; Sun-Woong Kang
Journal:  Biomater Res       Date:  2020-05-27

8.  A method for differentiating human induced pluripotent stem cells toward functional cardiomyocytes in 96-well microplates.

Authors:  Novin Balafkan; Sepideh Mostafavi; Manja Schubert; Richard Siller; Kristina Xiao Liang; Gareth Sullivan; Laurence A Bindoff
Journal:  Sci Rep       Date:  2020-10-28       Impact factor: 4.379

9.  A greedy classifier optimization strategy to assess ion channel blocking activity and pro-arrhythmia in hiPSC-cardiomyocytes.

Authors:  Fabien Raphel; Tessa De Korte; Damiano Lombardi; Stefan Braam; Jean-Frederic Gerbeau
Journal:  PLoS Comput Biol       Date:  2020-09-25       Impact factor: 4.475

10.  Rapid Targeted Method of Detecting Abused Piperazine Designer Drugs.

Authors:  Anna Welz; Marcin Koba; Piotr Kośliński; Joanna Siódmiak
Journal:  J Clin Med       Date:  2021-12-12       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.